Ginkgo Bioworks is a leading synthetic biology company that designs, builds, and tests new organisms for applications across industries. Founded in 2008 and headquartered in Boston, Massachusetts, Ginkgo has developed a platform for organism engineering that combines software, hardware, and biological innovation. The company went public on NASDAQ in 2021 (ticker: DNA) and has established itself as the premier synthetic biology foundry.
| Attribute |
Value |
| Headquarters |
Boston, Massachusetts, USA |
| Founded |
2008 |
| Ticker |
NASDAQ: DNA |
| Focus |
Synthetic biology, organism engineering |
| Employees |
1,000+ |
| Funding |
$2B+ raised |
Ginkgo's platform represents a new paradigm in biological engineering, combining high-throughput automation with sophisticated software tools:
- Automated laboratories: High-throughput strain design and testing
- Proprietary software: Biological design tools and machine learning
- Biosecurity programs: Pathogen detection and biosafety
| Capability |
Application |
| Strain engineering |
Improved production of therapeutics |
| Enzyme engineering |
Novel catalysis for drug manufacturing |
| Biosensor development |
Diagnostic and monitoring applications |
| Therapeutic protein production |
Manufacturing biologics |
| Genome engineering |
Customized organism design |
While Ginkgo Bioworks primarily focuses on industrial biotechnology, their platform has significant potential applications in neuroscience and neurodegeneration research:
Ginkgo's platform enables novel approaches to drug discovery for neurodegenerative diseases:
- Natural product synthesis: Engineering microorganisms to produce complex natural products with neuroprotective properties
- Enzyme inhibitor development: Developing novel enzyme inhibitors for neurodegenerative targets (e.g., beta-secretase, alpha-synuclein aggregation inhibitors)
- Biosensor development: Creating biosensors for detecting neurodegenerative biomarkers in patient samples
- Protein engineering: Engineering therapeutic proteins with improved brain penetration and efficacy
- Engineered cell lines: Providing engineered cell lines for disease modeling of Alzheimer's and Parkinson's
- Protein aggregation studies: Contributing to understanding of protein aggregation mechanisms
- Drug screening platforms: High-throughput screening using engineered cellular models
- Biologics production: Manufacturing complex biologic therapeutics
- Gene therapy vectors: Production of viral vectors for gene therapy
- Engineered probiotics: Live biotherapeutic approaches for neurological conditions
Ginkgo has established significant partnerships with pharmaceutical and biotechnology companies:
| Partner |
Focus Area |
| Roche/Genentech |
Antibody production optimization |
| Bayer |
Agricultural biotechnology |
| Cronos Group |
Cannabinoid production |
| Multiple therapeutics partners |
Undisclosed therapeutic programs |
- Public company: NASDAQ listing in September 2021
- Foundry expansion: Continued investment in automation and capacity
- Horizon acquisition: Strategic acquisitions to expand capabilities
Ginkgo operates on multiple revenue streams:
- Foundry services: Fee-for-service organism engineering
- Platform access: Partner access to proprietary tools
- Joint ventures: Equity partnerships in specific therapeutic areas
- Royalties: Revenue from successfully commercialized products
While Ginkgo is not specifically focused on neurodegeneration, their platform is relevant to:
- Drug discovery: High-throughput screening for AD/PD drug candidates
- Biomarker detection: Biosensors for early diagnosis
- Therapeutic manufacturing: Production of biologic drugs
- Disease modeling: Engineered systems for understanding disease mechanisms
The synthetic biology approach offers potential for developing novel disease-modifying therapies that target underlying mechanisms of neurodegeneration, rather than just symptoms.
¶ Competitive Landscape
Ginkgo Bioworks competes in the synthetic biology space with:
- Amyris: Renewable products company
- Gevo: Renewable chemicals
- Twist Bioscience: DNA synthesis
- Zymergen (now part of Ginkgo): Synthetic biology platform
Ginkgo maintains advantages through:
- Scale: Largest automated foundry
- Software: Proprietary design tools
- Track record: Proven platform
- Neurology focus: Increasing focus on CNS applications
- Partnership development: Additional pharma partnerships in neurodegeneration
- Internal programs: Potential development of proprietary therapeutics
- AI integration: Enhanced machine learning for biological design
- New modalities: Expanded capabilities in gene therapy, cell therapy
- Manufacturing: Scale-up of therapeutic production capabilities